Here’s a shocking revelation: despite its widespread use in type 2 diabetes, metformin has failed to show any significant improvement in insulin resistance for individuals with type 1 diabetes. This finding comes from the groundbreaking INTIMET study, which compared metformin to a placebo in assessing insulin resistance in liver, muscle, and adipose tissue. But here’s where it gets even more intriguing: while metformin is celebrated for its ability to enhance glucose metabolism and reduce insulin doses in type 2 diabetes, its effectiveness in type 1 diabetes remains a mystery—and this is the part most people miss. Let’s dive deeper into why this matters and what it means for the future of diabetes management.
Metformin, a cost-effective and safe oral medication, has long been a cornerstone in treating type 2 diabetes. Studies have consistently shown its ability to modify glucose metabolism in muscle and liver tissues, often measured using the hyperinsulinemic-euglycemic clamp technique. Additionally, it has been linked to reduced daily insulin requirements, which many interpret as an improvement in insulin resistance. However, when it comes to type 1 diabetes, the story takes an unexpected turn. As highlighted by endocrinologist Jennifer Snaith and her team at the Garvan Institute of Medical Research, previous studies using the gold-standard clamp technique to measure insulin resistance in type 1 diabetes have only focused on adolescents. This leaves a critical gap in understanding its effects on adults—a gap the INTIMET study aimed to fill.
The INTIMET study began as a cross-sectional investigation, examining insulin resistance in muscle, liver, and adipose tissue among adults with and without type 1 diabetes. It later evolved into a 6-month randomized controlled trial, testing whether adding metformin to insulin therapy could reduce hepatic insulin resistance and improve cardiometabolic markers in adults with type 1 diabetes. Participants, aged 20 to 55, had lived with type 1 diabetes for at least 10 years and met specific criteria for fasting c-peptide and HbA1c levels. Notably, those on medications or with conditions affecting insulin sensitivity were excluded to ensure the study’s integrity.
Insulin resistance was meticulously assessed using the 3-stage hyperinsulinemic-euglycemic clamp technique with isotope-labelled glucose. The primary focus was on changes in endogenous glucose production (EGP) during the low-dose phase of the clamp. Out of 40 enrolled participants—20 with type 1 diabetes and 20 without—37 completed the study. The results were striking: after 26 weeks, there was no significant difference in EGP between the metformin and placebo groups. Equally important, neither group experienced increased episodes of hypoglycemia or ketoacidosis.
These findings challenge the notion that metformin can effectively reduce insulin resistance in adults with type 1 diabetes. However, they suggest that metformin might still lower insulin requirements through mechanisms unrelated to insulin resistance. But here’s the controversial part: could metformin’s potential cardiovascular benefits, such as insulin sparing and reducing peripheral hyperinsulinemia, outweigh its limitations in this context? This question opens the door to further research and debate.
As Snaith and her colleagues aptly noted, while metformin may not be the silver bullet for insulin resistance in type 1 diabetes, its other potential benefits warrant closer examination. What do you think? Is metformin still worth exploring for type 1 diabetes, or should we focus on other therapies? Share your thoughts in the comments below and join the conversation!
